Ryan et al. 2023 — SELECT: Cardiovascular Outcomes

Semaglutide 2.4mg reduced major adverse cardiovascular events by 20% over 39 months in 17,604 obese patients with established cardiovascular disease.

Abstract

17,604 patient trial showing 20% MACE reduction with semaglutide in non-diabetic obese patients with CVD.

Key Findings

Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in patients with obesity and established cardiovascular disease over 39 months. This was the first GLP-1 receptor agonist for weight management to demonstrate CV benefit.

Study Design

Randomized controlled trial (SELECT)